NCT03652233View on ClinicalTrials.gov

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 2, 2018

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2022

Conditions
Recurrent Squamous Cell Carcinoma of the Head or NeckMetastatic Squamous Cell Carcinoma of the Head or NeckSquamous Cell Carcinoma
Interventions
DRUG

Nivolumab

Given by vein every 14 days for up to 12 months

DRUG

Afatinib

Taken by mouth daily for up to 12 months

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT03652233 - Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter